Status:
TERMINATED
Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension
Lead Sponsor:
Creighton University
Conditions:
Myocardial Remodeling
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
The goal of this project is to investigate the effects that the addition of aldosterone blockade with eplerenone will have on the progression of diastolic dysfunction in patients with controlled essen...
Detailed Description
The purpose of this project is to determine if eplerenone, an aldosterone blocker, prevents remodelling of the heart in patients with controlled essential hypertension, defined as having a blood press...
Eligibility Criteria
Inclusion
- Treated and controlled hypertension
- Less than 140/90 in non-diabetics
- Less than 130/80 in diabetics
Exclusion
- currently receiving an aldosterone blocker
- clinical evidence of congestive heart failure
- prior myocardial infarction
- renal dysfunction with a creatinine clearance of less than 40ml/min
- serum potassium \> 5.5meq/L at initiation
- concomitant use of a medication that inhibits the CYP3A4 enzyme (ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir)
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00980031
Start Date
April 1 2007
End Date
September 1 2011
Last Update
March 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Creighton University Medical Center (including ambulatory centers)
Omaha, Nebraska, United States, 68131